Approval · Notice of Compliance 2175 · 2001
CARDIZEM: Notice of Compliance 2175
Issued February 13, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2175
- Date
- February 13, 2001
- Company
- Crystaal, Division Of Biovail CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Antianginal agent, antihypertensive agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CARDIZEM | 02097370 | Cancelled Post Market |
| CARDIZEM | 02097389 | Cancelled Post Market |
| CARDIZEM SR | 02097214 | Cancelled Post Market |
| CARDIZEM SR | 02097222 | Cancelled Post Market |
| CARDIZEM SR | 02097230 | Cancelled Post Market |
| CARDIZEM CD CAPSULES | 02097257 | Dormant |
| CARDIZEM CD CAPSULES | 02097265 | Dormant |
| CARDIZEM CD CAPSULES | 02097273 | Dormant |
| CARDIZEM CD CAPSULES | 02097249 | Dormant |
Medicinal ingredients
- DILTIAZEM HCL 30 MG per TAB
- DILTIAZEM HCL 60 MG per TAB
- DILTIAZEM HCL 60 MG per CAP
- DILTIAZEM HCL 90 MG per CAP
- DILTIAZEM HCL 120 MG per CAP
- DILTIAZEM HCL 180 MG per CAP
- DILTIAZEM HCL 240 MG per CAP
- DILTIAZEM HCL 300 MG per CAP